Introduction/Aim. Adrenal incidentalomas (AIs) are defined as tumours revealed during imaging procedures of abdomen or abdominal laparotomy, performed in patients without previous suspicion for adrenal disease. This study was conducted to evaluate morphological and functional features of AIs seven years after the initial diagnosis. Patients and methods. Thirty-eight AI patients were monitored for seven years, with CT scans used for morphological follow-up. Hormonal activity assessments included basal cortisol levels, adrenocorticotropic hormone, overnight Dexamethasone suppression test, plasma or urinary metanephrines, vanillymandelic acid, electrolytes, hematocrit, acid-base status, oral glucose tolerance test, and chromogranin A. Results. Functional activity was confirmed in six patients, with mild autonomous cortisol secretion (MACS) detected in two patients. Nine patients underwent adrenalectomy. Histopathological examination revealed hormonal activity in six cases, adrenocortical carcinoma was found in one patient, while secondary deposits from bronchial carcinoma were detected in one patient. Among the remaining 29 patients observed for the first year, tumor size remained stable. After seven years, two patients experienced tumor enlargement ≥ 1 cm, along with the development of MACS on endocrine evaluation. Adrenalectomy was recommended for one patient due to tumor size exceeding 4 cm. Conclusion. The initial adrenal incidentaloma (AI) evaluation must include comprehensive diagnostic procedures for surgical consideration. Subsequent follow-up should include CT imaging after 12 months to monitor the tumor growth. Although mild autonomous cortisol secretion does not tend to progress to overt Cushing's syndrome, it can develop in patients initially considered to have hormonally inactive tumor. Our findings suggest that even small adrenal masses (< 4 cm) can enlarge over seven years, potentially evolving into MACS. Therefore, regular long-term monitoring every 5 - 7 years is recommended.
References
1.
Cesmebasi A, Du Plessis M, Iannatuono M, Shah S, Tubbs RS, Loukas M. A review of the anatomy and clinical significance of adrenal veins. Clinical Anatomy. 2014;27(8):1253–63.
2.
Jeong HS, Kim HJ, Kim HS, Kim SW, Shin CS, Park DJ, et al. Clinical Characteristics for 132 Patients with Adrenal Incidentaloma. Journal of Korean Endocrine Society. 2007;22(4):260.
3.
Latronico AC, Chrousos GP. Adrenocortical Tumors*. The Journal of Clinical Endocrinology & Metabolism. 1997;82(5):1317–24.
4.
Arnold DT, Reed JB, Burt K. Evaluation and Management of the Incidental Adrenal Mass. Baylor University Medical Center Proceedings. 2003;16(1):7–12.
5.
Moreira SG, Pow-Sang JM. Evaluation and Management of Adrenal Masses. Cancer Control. 2002;9(4):326–34.
6.
Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A, Newell-Price J, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. European Journal of Endocrinology. 2023;189(1):G1–42.
7.
Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. European Journal of Endocrinology. 2016;175(2):G1–34.
8.
Hao M, Lopez D, Luque-Fernandez MA, Cote K, Newfield J, Connors M, et al. The Lateralizing Asymmetry of Adrenal Adenomas. Journal of the Endocrine Society. 2018;2(4):374–85.
9.
Ahn SH, Kim JH, Baek SH, Kim H, Cho YY, Suh S, et al. Characteristics of Adrenal Incidentalomas in a Large, Prospective Computed Tomography-Based Multicenter Study: The COAR Study in Korea. Yonsei Medical Journal. 2018;59(4):501.
10.
Young WF. The Incidentally Discovered Adrenal Mass. New England Journal of Medicine. 2007;356(6):601–10.
11.
Rashed WM, Saad A, Al-Husseini M, Galal AM, Ismael AM, Al-Tayep AM, et al. Incidence of adrenal gland tumor as a second primary malignancy: SEER-based study. Endocrine Connections. 2018;7(10):1040–8.
12.
Grumbach MM, Biller BMK, Braunstein GD, Campbell KK, Carney JA, Godley PA, et al. Management of the Clinically Inapparent Adrenal Mass (Incidentaloma). Annals of Internal Medicine. 2003;138(5):424–9.
13.
Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. European Journal of Endocrinology. 2003;273–85.
14.
Nader S, Hickey RC, Sellin RV, Samaan NA. Adrenal cortical carcinoma a study of 77 cases. Cancer. 1983;52(4):707–11.
15.
Mantero F, Masini AM, Opocher G, Giovagnetti M, Arnaldi G. Adrenal Incidentaloma: An Overview of Hormonal Data from the National Italian Study Group. Hormone Research. 1997;47(4–6):284–9.
16.
Kim J, Bae KH, Choi YK, Jeong JY, Park KG, Kim JG, et al. Clinical Characteristics for 348 Patients with Adrenal Incidentaloma. Endocrinology and Metabolism. 2013;28(1):20.
17.
Androulakis II, Kaltsas G, Piaditis G, Grossman AB. The clinical significance of adrenal incidentalomas. European Journal of Clinical Investigation. 2011;41(5):552–60.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
